Global Neuroendocrine Tumors Market - Industry Trends and Forecast to 2028

Segmentation

Short Description Global Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI)), Grade (Grade 1 (Low-Grade Tumor, Grade 2 (Intermediate-Grade Tumor, Grade 3 (High-Grade Tumor)), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028 Market Definition: The initiation of tumor takes place when the DNA of healthy cells is damaged which causes the cells to change and grow in an uncontrolled manner, hence forming an aggregated mass of cells. A tumor can be cancerous and benign. A malignant cancerous tumor grows and spreads to other parts of the body if it is not found early and treated. A benign tumor can grow but will not spread. A benign tumor usually can be removed with use of minimally invasive surgery without it causing much harm. Market Segmentation: The neuroendocrine tumors market is segmented on the basis of the classification, site, grade, type, route of administration, end user and distribution channel. On the basis of classification, the neuroendocrine tumors market is segmented into functional net and non-functional net On the basis of site, the neuroendocrine tumors market is segmented into lung, pancreas and gastrointestinal tract (GI) On the basis of grade, the neuroendocrine tumors market is segmented into grade 1 (low-grade tumor), grade 2 (intermediate-grade tumor) and grade 3 (high-grade tumor) On the basis of type, the neuroendocrine tumors market is segmented into diagnosis and treatment On the basis of route of administration, the neuroendocrine tumors market is segmented into oral and parenteral On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others Market Players The key market players for global neuroendocrine tumors market are listed below: F. Hoffmann-La Roche Ltd Bristol-Myers Squibb Company Viatris Inc. Thermo Fisher Scientific Inc. Novartis AG Regeneron Pharmaceuticals, Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Eli Lilly and Company LUPIN Exact Sciences Corporation Pfizer Inc. Ipsen Pharma Advanced Accelerator Applications (a subsidiary of Novartis AG) BioSynthema Inc. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Bionano Genomics callistopharma Illumina, Inc. GlaxoSmithKline plc Hutchison China MediTech Limited

Methodology